「母亲迈向赋权」干预以减少博茨瓦纳HIV感染孕妇的污名并改善治疗依从性:实用性临床试验研究方案
本研究为在博茨瓦纳开展的实用性临床试验方案,评估「母亲迈向赋权」(MME)干预相比常规治疗(TAU)对HIV感染孕妇及其婴儿的效果。MME基于「最重要之事」污名框架,孕妇按预产期分组,在孕36周前完成最多8次小组干预。主要结局包括减少自我污名、心理结局及产前保健和抗逆转录病毒治疗(ART)依从性,并随访婴儿出生结局。
要点
- MME干预基于文化情境的污名框架,针对HIV感染孕妇设计。
- 主要结局为自我污名、心理结局及产前保健和ART依从性。
- 同时评估婴儿APGAR评分、早产、死亡、出生体重、疫苗接种和HIV状态。
核心结论
- 本研究将评估基于「最重要之事」框架的文化情境HIV污名减少干预MME,以减少孕妇及其婴儿的污名并改善治疗依从性。
- 研究结果将有助于进一步完善MME,并为未来在博茨瓦纳开展大规模多中心随机对照试验(RCT)做准备。
研究设计与样本
- 实用性临床试验,在博茨瓦纳比较MME与常规治疗(TAU)。
- 对象为确诊HIV的孕妇及其婴儿,在孕期和产后16周评估结局。
- 符合标准的女性被分配到MME或TAU组;MME组按估计分娩日期分组,在孕36周前完成最多8次干预小组课程。
关键数值与推荐
- 主要结局包括减少自我污名(假设其介导心理结局和依从性改善)、心理结局(生活质量、抑郁和社会功能)以及产前保健和ART依从性。
- 婴儿随访结局包括APGAR评分、早产、死亡(<16周)、出生体重、疫苗接种记录和HIV状态。
临床怎么用
- MME为文化情境化的HIV污名减少干预,可整合至HIV感染孕妇的产前保健服务中。
- 干预在孕36周前以小组形式开展,最多8次课程,按预产期分组。
局限性
- 本文为研究方案,尚未报告干预效果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With high rates of HIV and multiple vulnerable subgroups across diverse settings, there is a need for culturally based, HIV stigma reduction interventions. Pregnant women who are living with HIV are especially in need of services to protect not only their own but also their children's lives. Uptake of HIV services worldwide is hindered by stigma towards persons living with HIV/AIDS. While cultural context plays a key role in shaping HIV stigma, these insights have not yet been fully integrated into stigma reduction strategies. By utilizing the "What Matters Most" stigma framework, we propose that an intervention to counter culturally salient aspects of HIV stigma will improve treatment adherence and other relevant outcomes. A pragmatic clinical trial in Botswana will evaluate the "Mothers Moving towards Empowerment" (MME) intervention, which seeks to address HIV stigma in Botswana and to specifically engage pregnant mothers so as to promote antiretroviral therapy (ART) adherence in the postpartum period. METHODS: This study will test MME against treatment as usual (TAU) among pregnant mothers diagnosed with HIV and their infants. Outcomes will be assessed during pregnancy and 16 weeks postpartum. Women who meet eligibility criteria are assigned to MME or TAU. Women assigned to MME are grouped with others with similar estimated delivery dates, completing up to eight intervention group sessions scheduled before week 36 of their pregnancies. Primary outcomes among mothers include (i) reducing self-stigma, which is hypothesized to mediate improvements in (ii) psychological outcomes (quality of life, depression and social functioning), and (iii) adherence to antenatal care and ART. We will also examine a set of follow-up infant birth outcomes (APGAR score, preterm delivery, mortality (at < 16 weeks), birth weight, vaccination record, and HIV status). DISCUSSION: Our trial will evaluate MME, a culturally based HIV stigma reduction intervention using the "What Matters Most" framework, to reduce stigma and improve treatment adherence among pregnant women and their infants. This study will help inform further refinement of MME and preparation for a future large-scale, multisite, randomized controlled trial (RCT) in Botswana. TRIAL REGISTRATION: ClinicalTrials.gov NCT03698981 . Registered on October 8, 2018.
引用
- Poku OB, Ho-Foster AR, Entaile P, et al. 'Mothers moving towards empowerment' intervention to reduce stigma and improve treatment adherence in pregnant women living with HIV in Botswana: study protocol for a pragmatic clinical trial. Trials. 2020. PMID: 33028387. doi:10.1186/s13063-020-04676-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。